Clinical and biological significance of hepatoma-derived growth factor in Ewing's sarcoma

Journal of Pathology

Volumn 231, Issue 3, 2013, Pages 323-334

  Yang, Yang ^a   Li, Hui ^a   Zhang, Fenfen ^a   Shi, Huijuan ^a   Zhen, Tiantian ^a   Dai, Sujuan ^a   Kang, Lili ^a   Liang, Yingjie ^a   Wang, Jin ^a   Han, Anjia ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

biological significance; clinicopathology; Ewing's sarcoma; hepatoma derived growth factor

Indexed keywords

COMPLEMENTARY DNA; HEPATOMA DERIVED GROWTH FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BIOLOGICAL FUNCTIONS; CANCER PROGNOSIS; CARCINOGENESIS; CELL CYCLE ARREST; CELL CYCLE PROGRESSION; CELL GROWTH; CELL PROLIFERATION; CLINICAL FEATURE; DISEASE FREE SURVIVAL; DOWNSTREAM PROCESSING; EWING SARCOMA; FEMALE; HUMAN; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MICROARRAY ANALYSIS; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SARCOMA CELL; SURVIVAL RATE; TUMOR VOLUME; UPREGULATION;

BIOLOGICAL SIGNIFICANCE; CLINICOPATHOLOGY; EWING'S SARCOMA; HEPATOMA-DERIVED GROWTH FACTOR;

ANIMALS; APOPTOSIS; BONE NEOPLASMS; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL PROLIFERATION; CHI-SQUARE DISTRIBUTION; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; KAPLAN-MEIER ESTIMATE; MICE; MICE, INBRED BALB C; MICE, NUDE; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODELS; RNA INTERFERENCE; SARCOMA, EWING; TIME FACTORS; TRANSFECTION; TUMOR BURDEN; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 84885420419     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.4241     Document Type: Article

References (35)

1. Delattre O, Zucman J, Plougastel B, et al., Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours. Nature 1992; 359: 162-165.
2. de Alava E, Kawai A, Healey JH, et al., EWS-FLI1 fusion transcript structure is an independent determinant of prognosis in Ewing's sarcoma. J Clin Oncol 1998; 16: 1248-1255.
3. Zoubek A, Dockhorn-Dworniczak B, Delattre O, et al., Does expression of different EWS chimeric transcripts define clinically distinct risk groups of Ewing tumor patients? J Clin Oncol 1996; 14: 1245-1251.
4. van Doorninck JA, Ji L, Schaub B, et al., Current treatment protocols have eliminated the prognostic advantage of type 1 fusions in Ewing sarcoma: a report from the Children's Oncology Group. J Clin Oncol 2010; 28: 1989-1994.
5. Le Deley MC, Delattre O, Schaefer KL, et al., Impact of EWS-ETS fusion type on disease progression in Ewing's sarcoma/peripheral primitive neuroectodermal tumor: prospective results from the cooperative Euro-EWING 99 trial. J Clin Oncol 2010; 28: 1982-1988.
6. Savola S, Klami A, Tripathi A, et al., Combined use of expression and CGH arrays pinpoints novel candidate genes in Ewing sarcoma family of tumors. BMC Cancer 2009; 9: 17.
7. Nakamura H, Izumoto Y, Kambe H, et al., Molecular cloning of complementary DNA for a novel human hepatoma-derived growth factor. Its homology with high mobility group-1 protein. J Biol Chem 1994; 269: 25143-25149.
8. Nakamura H, Kambe H, Egawa T, et al., Partial purification and characterization of human hepatoma-derived growth factor. Clin Chim Acta 1989; 183: 273-284.
9. Enomoto H, Yoshida K, Kishima Y, et al., Hepatoma-derived growth factor is highly expressed in developing liver and promotes fetal hepatocyte proliferation. Hepatology 2002; 36: 1519-1527.
10. Everett AD,. Identification, cloning, and developmental expression of hepatoma-derived growth factor in the developing rat heart. Dev Dyn 2001; 222: 450-458.
11. Everett AD, Stoops T, McNamara CA,. Nuclear targeting is required for hepatoma-derived growth factor-stimulated mitogenesis in vascular smooth muscle cells. J Biol Chem 2001; 276: 37564-37568.
12. Everett AD, Lobe DR, Matsumura ME, et al., Hepatoma-derived growth factor stimulates smooth muscle cell growth and is expressed in vascular development. J Clin Invest 2000; 105: 567-575.
13. Oliver JA, Al-Awqati Q,. An endothelial growth factor involved in rat renal development. J Clin Invest 1998; 102: 1208-1219.
14. Yamamoto S, Tomita Y, Hoshida Y, et al., Expression level of hepatoma-derived growth factor correlates with tumor recurrence of esophageal carcinoma. Ann Surg Oncol 2007; 14: 2141-2149.
15. Uyama H, Tomita Y, Nakamura H, et al., Hepatoma-derived growth factor is a novel prognostic factor for patients with pancreatic cancer. Clin Cancer Res 2006; 12: 6043-6048.
16. Yamamoto S, Tomita Y, Hoshida Y, et al., Expression of hepatoma-derived growth factor is correlated with lymph node metastasis and prognosis of gastric carcinoma. Clin Cancer Res 2006; 12: 117-122.
17. Yoshida K, Tomita Y, Okuda Y, et al., Hepatoma-derived growth factor is a novel prognostic factor for hepatocellular carcinoma. Ann Surg Oncol 2006; 13: 159-167.
18. Ren H, Tang X, Lee JJ, et al., Expression of hepatoma-derived growth factor is a strong prognostic predictor for patients with early-stage non-small-cell lung cancer. J Clin Oncol 2004; 22: 3230-3237.
19. Lin YW, Li CF, Chen HY, et al., The expression and prognostic significance of hepatoma-derived growth factor in oral cancer. Oral Oncol 2012; 48: 629-635.
20. Zhang J, Ren H, Yuan P, et al., Down-regulation of hepatoma-derived growth factor inhibits anchorage-independent growth and invasion of non-small cell lung cancer cells. Cancer Res 2006; 66: 18-23.
21. Machuy N, Thiede B, Rajalingam K, et al., A global approach combining proteome analysis and phenotypic screening with RNA interference yields novel apoptosis regulators. Mol Cell Proteom 2005; 4: 44-55.
22. Shen XY, Zacal N, Singh G, et al., Alterations in mitochondrial and apoptosis-regulating gene expression in photodynamic therapy-resistant variants of HT29 colon carcinoma cells. Photochem Photobiol 2005; 81: 306-313.
23. Yang J, Everett AD,. Hepatoma-derived growth factor binds DNA through the N-terminal PWWP domain. BMC Mol Biol 2007; 8: 101.
24. Kishima Y, Yamamoto H, Izumoto Y, et al., Hepatoma-derived growth factor stimulates cell growth after translocation to the nucleus by nuclear localization signals. J Biol Chem 2002; 277: 10315-10322.
25. Nameki N, Tochio N, Koshiba S, et al., Solution structure of the PWWP domain of the hepatoma-derived growth factor family. Protein Sci 2005; 14: 756-764.
26. Meng F, Li H, Shi H, et al., MACC1 down-regulation inhibits proliferation and tumourigenicity of nasopharyngeal carcinoma cells through Akt/β-catenin signaling pathway. PLoS One 2013; 8: e60821.
27. Czauderna F, Fechtner M, Dames S, et al., Structural variations and stabilising modifications of synthetic siRNAs in mammalian cells. Nucleic Acids Res 2003; 31: 2705-2716.
28. Cotterill SJ, Ahrens S, Paulussen M, et al., Prognostic factors in Ewing's tumor of bone: analysis of 975 patients from the European Intergroup Cooperative Ewing's Sarcoma Study Group. J Clin Oncol 2000; 18: 3108-3114.
29. Baird K, Davis S, Antonescu CR, et al., Gene expression profiling of human sarcomas: insights into sarcoma biology. Cancer Res 2005; 65: 9226-9235.
30. Nakatani F, Ferracin M, Manara MC, et al., miR-34a predicts survival of Ewing's sarcoma patients and directly influences cell chemo-sensitivity and malignancy. J Pathol 2012; 226: 796-805.
31. Grunewald TG, Ranft A, Esposito I, et al., High STEAP1 expression is associated with improved outcome of Ewing's sarcoma patients. Ann Oncol 2012; 23: 2185-2190.
32. Bennani-Baiti IM, Cooper A, Lawlor ER, et al., Intercohort gene expression co-analysis reveals chemokine receptors as prognostic indicators in Ewing's sarcoma. Clin Cancer Res 2010; 16: 3769-3778.
33. de Alava E, Antonescu CR, Panizo A, et al., Prognostic impact of P53 status in Ewing sarcoma. Cancer 2000; 89: 783-792.
34. Ren H, Chu Z, Mao L,. Antibodies targeting hepatoma-derived growth factor as a novel strategy in treating lung cancer. Mol Cancer Ther 2009; 8: 1106-1112.
35. Chen SC, Kung ML, Hu TH, et al., Hepatoma-derived growth factor regulates breast cancer cell invasion by modulating epithelial-mesenchymal transition. J Pathol 2012; 228: 158-169.